In the latest addition to the growing cornucopia of ideas for how to turn RNAs into medicines, scientists are now developing synthetic versions of a historically …
FDA seeks to encourage fewer animal studies with new draft guidance
The FDA unveiled long-awaited draft guidance on how biopharma companies can validate new approaches for toxicology and other early-phase safety studies, potentially reducing the animal



